

Mechanical and manual chest compressions for resuscitation in in-hospital cardiac arrest

Submission date 09/01/2017	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 12/01/2017	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 14/10/2020	Condition category Circulatory System	☐ Individual participant data

Plain English summary of protocol

Background and study aims

A cardiac arrest is a serious medical condition where the heart suddenly stops pumping blood around the body. It can be fatal and so when someone has a cardiac arrest, immediate treatment is essential. Chest compressions are an essential treatment for cardiac arrest patients, but are often difficult for a person to deliver to a high standard (manual chest compressions). A mechanical chest compression device can be used to deliver chest compressions (mechanical chest compressions) instead of a person. Every year, 35,000 patients have a cardiac arrest in UK hospitals. However, less than one in five patients survives to leave hospital. When someone has a cardiac arrest, immediate treatment is essential. Small studies suggest using these devices may improve patient survival when used as part of treatment for cardiac arrest patients in hospital. The aim of this study is to conduct a small-scale study in order to find out if a large study looking comparing these two treatments would be feasible.

Who can participate?

Adults whose heart stops while they are in hospital.

What does the study involve?

Patients who have a cardiac arrest all receive manual (by hand) chest compressions initially. When the device arrives at the cardiac arrest, eligible patients are randomly allocated to continue receiving manual chest compressions or to switch to mechanical (delivered by a machine) chest compressions. For all participants, the allocated treatment is delivered for the duration of the cardiac arrest (usually between 20 minutes and two hours). Participants in both groups are followed up until they are discharged from hospital and again 30 days and six months later. Follow up involves the researchers reviewing medical records and participants completing questionnaires about their quality of life.

What are the possible benefits and risks of participating?

The key potential benefit associated with use of the mechanical device is the possibility of improved delivery of chest compressions. The key risk is that deployment of the device requires short pauses in chest compressions. Cardiac arrest teams deploying the device will receive special training so that they can use devices effectively.

Where is the study run from?

1. Birmingham Heartlands Hospital (UK)
2. University Hospital Coventry (UK)
3. Sandwell General Hospital (UK)
4. Warwick Hospital (UK)
5. Blackpool Hospital (UK)

When is the study starting and how long is it expected to run for?

October 2015 to September 2019

Who is funding the study?

National Institute for Health Research (UK)

Who is the main contact?

Dr Keith Couper

compresstrial@warwick.ac.uk

Contact information

Type(s)

Public

Contact name

Dr Keith Couper

ORCID ID

<https://orcid.org/0000-0003-2123-2022>

Contact details

Clinical Trials Unit

University of Warwick

Coventry

United Kingdom

CV4 7AL

+44 2476 575923

compresstrial@warwick.ac.uk

Additional identifiers

Protocol serial number

33216

Study information

Scientific Title

A feasibility randomised controlled trial of mechanical chest compression devices for in-hospital cardiac arrest (COMPRESS-RCT)

Acronym

COMPRESS-RCT

Study objectives

The aim of this study is to assess the feasibility of undertaking a randomised controlled effectiveness trial of mechanical chest compression devices in in-hospital cardiac arrest.

Ethics approval required

Old ethics approval format

Ethics approval(s)

West Midlands - Coventry & Warwickshire Research Ethics Committee, 12/09/2016, ref :16/WM/0299

Study design

Randomised; Both; Design type: Treatment, Device, Qualitative

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Specialty: Cardiovascular disease, Primary sub-specialty: Heart Failure; UKCRC code/ Disease: Cardiovascular/ Other forms of heart disease

Interventions

Participants are randomised in a 3:1 ratio to receive either mechanical chest compressions or manual chest compressions. Randomisation will be done by opening an opaque envelope that is kept with the device following confirmation of eligibility.

Participants in the mechanical chest compression arm will receive mechanical chest compressions delivered by the LUCAS-2 or LUCAS-3 device (Joliffe AB/ Physio-Control, Lund, Sweden).

Participants in the manual chest compression arm will continue to receive chest compressions delivered by a human.

The allocated treatment will be delivered for the duration of the cardiac arrest event (usually around 20-minutes, but may be up to two hours).

Participants will be followed-up to six-months and consists of review of medical records and completion of quality of life questionnaires.

Intervention Type

Other

Primary outcome(s)

Current Primary outcome measure, as of 21/03/2018:

Proportion of eligible patients that are randomised during operational recruitment hours over the entire study period.

Previous Primary outcome measure:

Proportion of eligible participants randomised over the entire study period

Key secondary outcome(s))

Feasibility outcome measures:

1. Proportion of patients randomised outside of weekday daytime hours is assessed at the end of the study
2. Device deployment time (compression pause associated with device deployment) is assessed at the end of the study
3. Proportion of patients/consultees agreeing to ongoing study participation is assessed at the end of the study
4. Success of study blinding procedures is assessed at the end of the study
5. Proportion of patients with complete follow-up data is assessed at the end of the study
6. Proportion of patients with analysable chest compression quality data is assessed at the end of the study

Patient outcome measures:

1. Return of spontaneous circulation is assessed by reviewing patient notes 20 minutes following cardiac arrest
2. Survival is assessed by reviewing patient notes at hospital discharge, 30 days and 6 months
3. Neurological outcome is assessed using the cerebral performance category at discharge and modified rankin score at discharge and 6 months
4. Hospital/critical care length of stay is measured by reviewing patient notes at the time of discharge
5. Quality of life is measured using the EQ-5D and SF-12 at discharge and 6 months

Process outcome measure:

CPR quality (rate, depth, flow-fraction, pauses- pre-,post-, peri-shock) is assessed by reviewing defibrillator and/ or mechanical device data during cardiac arrest.

Safety outcome measure:

Device related adverse events are measured by reviewing patient notes up to the point of discharge

Completion date

30/09/2019

Eligibility

Key inclusion criteria

1. Sustain an in-hospital cardiac arrest and resuscitation is attempted by a hospital cardiac arrest team trained in the use of the mechanical chest compression device
2. In a non-shockable rhythm (pulseless electrical activity or asystole) at the time of eligibility assessment
3. Known or believed to be aged 18 years or over

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

127

Key exclusion criteria

1. Patient has valid do not attempt cardiopulmonary resuscitation order
2. Known or clinically apparent pregnancy
3. Cardiac arrest where use of a mechanical chest compression device is contra-indicated (e.g. following cardiac surgery, thoracic trauma, patient size)
4. Known previous study participation
5. Patient requiring use of mechanical chest compression device as part of routine clinical care
6. Patient known to be detained by Her Majesty's Prison Service

Date of first enrolment

31/01/2017

Date of final enrolment

31/01/2019

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Birmingham Heartlands Hospital**

Heart of England NHS Foundation Trust

Bordesley Green East

Birmingham

United Kingdom

B9 5SS

Study participating centre**University Hospital Coventry**

University Hospitals Coventry and Warwickshire NHS Trust

Clifford Bridge Road

Coventry
United Kingdom
CV2 2DX

Study participating centre
Sandwell General Hospital
Sandwell and West Birmingham Hospitals NHS Trust
Lyndon
West Bromwich
United Kingdom
B71 4HJ

Study participating centre
Warwick Hospital
South Warwickshire NHS Foundation Trust,
Lakin Road,
United Kingdom
CV34 5BW

Study participating centre
Blackpool Hospital
Blackpool Teaching Hospitals NHS Foundation Trust,
Whinney Heys
Blackpool
United Kingdom
FY3 8NR

Sponsor information

Organisation
University of Warwick

ROR
<https://ror.org/01a77tt86>

Funder(s)

Funder type
Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The current data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2019	14/08/2019	Yes	No
Results article	results	01/09/2019	14/08/2019	Yes	No
Results article	results	01/01/2021	14/10/2020	Yes	No
Protocol article	protocol	30/08/2018	14/08/2019	Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes